Numerous clinical trials for breast cancer treatment have now reached phase 3 studies. Below, you’ll find the latest on three of these new clinical trials dedicated to finding a cure for breast cancer. There are more clinical trials on the list that you can explore later. Each trial has different requirements to join.
The clinical trials are designed to treat specific conditions. The three main drugs from the trials include Enhertu, Keytruda, and Kadcyla, respectively. These are not the only new trials right now, though; there are many more emerging.
DESTINY-B12. This trial is for people who have been treated for advanced or metastatic HER2+ breast cancer. The treatment will last two and a half years. Patients will be treated with trastuzumab deruxtecan (Enhertu).
KEYNOTE-B49. If you have locally recurrent inoperable or metastatic HR+, HER2- breast cancer, you’re eligible for this clinical trial. This treatment will last up to two years. Researchers will be adding pembrolizumab (Keytruda) to your existing chemotherapy.
KATE3. To be eligible for this clinical trial, you need to have locally advanced or metastatic HER2+, PD-L1+ breast cancer. This study is being conducted in California, Georgia, Missouri, New Mexico, New York, and Pennsylvania. Researchers will look at the effects of combining trastuzumab emtansine (T-DM1, Kadcyla) with atezolizumab (Tecentriq). Of all the new clinical trials, KATE3 is the only one for which Overall Survival is the primary intended outcome.
If you’re interested in learning more, read about the new trials here.
